Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT versus SANOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT versus SANOREX.
MELFIAT vs SANOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect.
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Anorexiant
Anorexiant